Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer

被引:12
作者
Chen, Chen [1 ]
Wang, Tao [1 ]
Yang, Mengmei [2 ]
Song, Jia [2 ]
Huang, Mengli [2 ]
Bai, Yuezong [2 ]
Su, Hao [3 ]
机构
[1] Hunan Normal Univ, Hunan Prov Peoples Hosp, Hepatobiliary Surg, Affiliate Hosp 1, Changsha, Peoples R China
[2] 3D Med Inc, Dept Med, Shanghai, Peoples R China
[3] Guangxi Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Nanning, Peoples R China
关键词
next-generation sequencing; signaling pathway; circulating tumor DNA; biliary tract cancer; genomic feature; INTRAHEPATIC CHOLANGIOCARCINOMA; UNITED-STATES; OPEN-LABEL; GALLBLADDER; CHEMOTHERAPY; MULTICENTER; NOMOGRAM; RATES;
D O I
10.3389/pore.2021.1609879
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Biliary tract cancer is a highly lethal malignancy with poor clinical outcome. Accumulating evidence indicates targeted therapeutics may provide new hope for improving treatment response in BTC, hence better understanding the genomic profile is particularly important. Since tumor tissue may not be available for some patients, a complementary method is urgently needed. Circulating tumor DNA (ctDNA) provides a noninvasive means for detecting genomic alterations, and has been regarded as a promising tool to guide clinical therapies. Methods: Next-generation sequencing of 150 cancer-related genes was used to detect gene alterations in blood-derived ctDNA from 154 Chinese patients with BTC. Genomic alterations were analyzed and compared with an internal tissue genomic database and TCGA database. Results: 94.8% patients had at least one change detected in their ctDNA. The median maximum somatic allele frequency was 6.47% (ranging 0.1-34.8%). TP53 and KRAS were the most often mutated genes. The frequencies of single nucleotide variation in commonly mutated genes in ctDNA were similar to those detected in tissue samples, TP53 (35.1 vs. 40.4%) and KRAS (20.1 vs. 22.6%). Pathway analysis revealed that mutated genes were mapped to several key pathways including PI3K-Akt, p53, ErbB and Ras signaling pathway. In addition, patients harboring LRP1B, TP53, and ErbB family mutations presented significantly higher tumor mutation burden. Conclusions: These findings demonstrated that ctDNA testing by NGS was feasible in revealing genomic changes and could be a viable alternative to tissue biopsy in patients with metastatic BTC.
引用
收藏
页数:9
相关论文
共 37 条
[1]   Variations in DNA repair genomic alterations and tumor mutation burden in biliary tract cancer (BTC) subtypes. [J].
Abdel-Wahab, Reham ;
Ali, Siraj Mahamed ;
Borad, Mitesh J. ;
Shroff, Rachna T. ;
Kwong, Lawrence ;
Vauthey, Jean-Nicolas ;
Koay, Eugene Jon ;
Zuo, Mingxin ;
Rashid, Asif ;
Schrock, Alexa Betzig ;
Ross, Jeffrey S. ;
Bekaii-Saab, Tanios S. ;
Javle, Milind M. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[2]   Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [J].
Abou-Alfa, Ghassan K. ;
Macarulla, Teresa ;
Javle, Milind M. ;
Kelley, Robin K. ;
Lubner, Sam J. ;
Adeva, Jorge ;
Cleary, James M. ;
Catenacci, Daniel V. ;
Borad, Mitesh J. ;
Bridgewater, John ;
Harris, William P. ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Whisenant, Jonathan ;
Lowery, Maeve A. ;
Goyal, Lipika ;
Shroff, Rachna T. ;
El-Khoueiry, Anthony B. ;
Fan, Bin ;
Wu, Bin ;
Chamberlain, Christina X. ;
Jiang, Liewen ;
Gliser, Camelia ;
Pandya, Shuchi S. ;
Valle, Juan W. ;
Zhu, Andrew X. .
LANCET ONCOLOGY, 2020, 21 (06) :796-807
[3]   Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].
Abou-Alfa, Ghassan K. ;
Sahai, Vaibhav ;
Hollebecque, Antoine ;
Vaccaro, Gina ;
Melisi, Davide ;
Al-Rajabi, Raed ;
Paulson, Andrew S. ;
Borad, Mitesh J. ;
Gallinson, David ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Dotan, Efrat ;
Catenacci, Daniel, V ;
Van Cutsem, Eric ;
Ji, Tao ;
Lihou, Christine F. ;
Zhen, Huiling ;
Feliz, Luis ;
Vogel, Arndt .
LANCET ONCOLOGY, 2020, 21 (05) :671-684
[4]   Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation [J].
Athauda, Avani ;
Fong, Caroline ;
Lau, David K. ;
Javle, Milind ;
Abou-Alfa, Ghassan K. ;
Morizane, Chigusa ;
Steward, Keith ;
Chau, Ian .
CANCER TREATMENT REVIEWS, 2020, 86
[5]   Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer [J].
Chae, Young Kwang ;
Davis, Andrew A. ;
Jain, Sarika ;
Santa-Maria, Cesar ;
Flaum, Lisa ;
Beaubier, Nike ;
Platanias, Leonidas C. ;
Gradishar, William ;
Giles, Francis J. ;
Cristofanilli, Massimo .
MOLECULAR CANCER THERAPEUTICS, 2017, 16 (07) :1412-1420
[6]   Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades [J].
Chen, Hao ;
Chong, Wei ;
Wu, Qian ;
Yao, Yueliang ;
Mao, Min ;
Wang, Xin .
FRONTIERS IN IMMUNOLOGY, 2019, 10
[7]   Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing [J].
Chen, Ke-Zhong ;
Lou, Feng ;
Yang, Fan ;
Zhang, Jing-Bo ;
Ye, Hua ;
Chen, Wei ;
Guan, Tian ;
Zhao, Ming-Yu ;
Su, Xue-Xia ;
Shi, Rong ;
Jones, Lindsey ;
Huang, Xue F. ;
Chen, Si-Yi ;
Wang, Jun .
SCIENTIFIC REPORTS, 2016, 6
[8]   Association between Variants in Atopy-Related Immunologic Candidate Genes and Pancreatic Cancer Risk [J].
Cotterchio, Michelle ;
Lowcock, Elizabeth ;
Bider-Canfield, Zoe ;
Lemire, Mathieu ;
Greenwood, Celia ;
Gallinger, Steven ;
Hudson, Thomas .
PLOS ONE, 2015, 10 (05)
[9]   Recurrent Targeted Genes of Hepatitis B Virus in the Liver Cancer Genomes Identified by a Next-Generation Sequencing-Based Approach [J].
Ding, Dong ;
Lou, Xiaoyan ;
Hua, Dasong ;
Yu, Wei ;
Li, Lisha ;
Wang, Jun ;
Gao, Feng ;
Zhao, Na ;
Ren, Guoping ;
Li, Lanjuan ;
Lin, Biaoyang .
PLOS GENETICS, 2012, 8 (12)
[10]   Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma [J].
Dong, Zhong-Yi ;
Zhong, Wen-Zhao ;
Zhang, Xu-Chao ;
Su, Jian ;
Xie, Zhi ;
Liu, Si-Yang ;
Tu, Hai-Yan ;
Chen, Hua-Jun ;
Sun, Yue-Li ;
Zhou, Qing ;
Yang, Jin-Ji ;
Yang, Xue-Ning ;
Lin, Jia-Xin ;
Yan, Hong-Hong ;
Zhai, Hao-Ran ;
Yan, Li-Xu ;
Liao, Ri-Qiang ;
Wu, Si-Pei ;
Wu, Yi-Long .
CLINICAL CANCER RESEARCH, 2017, 23 (12) :3012-3024